PRODIAP: See if patient-reported outcomes improve care for people with type 2 diabetes in general practice
Official title: PRODIAP - Patient-Reported Outcomes in General Practice Among People With Type 2 Diabetes
Run by University of Aarhus · NCT07767331 · Data updated 2026-11-12
A large Danish trial tests whether using a diabetes-specific patient-reported outcomes questionnaire in general practice helps tailor care for people with type 2 diabetes.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 2000 (estimated) |
| Sponsor | University of Aarhus Academic / other |
| Locations | 1 site (Aarhus) |
| Status | Recruiting |
| Started | March 1, 2026 |
| Main results expected | February 2028 |
| Study ends | February 2028 |
| Registry record updated | August 17, 2026 |
| Trial ID | NCT07767331 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with type 2 diabetes who can understand and answer a Danish questionnaire and receive care in general practice.
✕Probably not a fit
People who do not engage with questionnaires or whose care is not guided by PRO data may not experience benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
PRODIAP is a mixed-methods study in Denmark that tests whether a diabetes-specific PRO questionnaire used in general practice can improve the quality of care and support more individualized consultations for people with type 2 diabetes. The project uses a pragmatic cluster-randomised design across 30 general practices to compare usual care with PRO-informed care. It adapts hospital PRO tools for primary care, and pilot testing showed feasibility and acceptability. The study aims to understand how PRO data influence patient engagement, consultation content, and perceived care quality, with both quantitative and qualitative components.
Why it matters
Potential benefit: If successful, PRODIAP could lead to more patient-centered consultations and better alignment of care with patient needs in primary care.
How similar studies have gone: Previous work in type 1 diabetes and other settings suggests PROs can enhance engagement and communication, but evidence in type 2 diabetes primary care is limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * type 2 diabetes * able to understand and answer a Danish questionnaire Exclusion Criteria: * none
Where it's running
-
Steno Diabetes Center Aarhus
Aarhus, Denmark Recruiting
Study contacts
- Study coordinator: Anette Andersen, MD, PhD
- Email: anette.andersen@rm.dk
- Phone: +4522135605
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Acute Blood Flow Restriction Walking in Type 2 Diabetes
This study tests whether adding blood flow restriction to treadmill walking affects immune cells in adults with type 2 diabetes.
-
Continuous Glucose Monitoring in Type 2 Diabetes Not on Insulin
This study tests whether using a continuous glucose monitoring system helps people with type 2 diabetes who aren’t using insulin to improve blood sugar control and quality of life.
-
Differentiating heart disease in autoimmune vs. type 2 diabetes
This study tests whether adult-onset autoimmune diabetes (AID/LADA) and type 2 diabetes (T2D) differ in how diabetic heart disease develops, using advanced heart imaging in people with AID, T2D, and healthy controls.
-
Lifestyle Metabotype Study B: Understanding Personalized Glucose Responses
This study tests how lifestyle, metabolism, and brain energy use relate to each person’s blood sugar response after meals, across people with and without prediabetes or type 2 diabetes.
-
Lifestyle Metabotype Study: How Daily Habits Shape Blood Sugar
This observational study tests whether personal lifestyle and biological factors can predict how a person’s blood sugar responds after meals.
-
Switching to Zenagamtide From Tirzepatide in Adults With Overweight or Obesity With or Without Type 2 Diabetes
This study tests whether adults who are overweight or have obesity (with or without type 2 diabetes) can switch from tirzepatide to a new treatment called zenagamtide to find a tolerable dose.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.